Enzalutamide offers survival advantage over other NSAAs in mHSPC Presented ByDr Christopher Sweeney, Dana-Farber Cancer Institute, USA TrialENZAMET, TITAN ConferenceASCO 2019 TypePeer-reviewed article 15 July 2019 23:26